Latest News

“Australia is a big market for us and strategically very important,” said AbbVie's Pierre Claude Fumoleau. “It is also one of the 49 countries I manage. But, at the end of the day, the decisions Australians make about their system are for them to own.”

CLINUVEL Pharmaceuticals (ASX:CUV) has presented new evidence of its lead therapy SCENESSE (afamelanotide) delivering visible and lasting repigmentation in patients with vitiligo, one of the world’s most common pigmentary disorders.

An Australian-developed blood test has shown strong potential to transform outcomes for people at risk of esophageal adenocarcinoma (EAC), one of the most lethal cancers worldwide. Proteomics...

Island Pharmaceuticals (ASX:ILA) has secured a significant regulatory milestone, with the US FDA granting its request for a Type C meeting under the company’s open Investigational New Drug application for Galidesivir.

Proteomics International Laboratories (ASX:PIQ) has achieved a significant milestone in its expansion into precision medicine, securing ISO 15189 certification for its Australian diagnostic laboratory operations.

There is something uniquely indefensible about a politician using the tragic suffering of a family and the death of a child for political gain and then abandoning them when a technical advisory committee and its bureaucracy repudiate their basic request.

Health Minister Mark Butler has publicly acknowledged his concerns over the potential impact in Australia of the Trump administration's 'Most Favored Nation' pharmaceutical pricing policy.

The leader of the new search function will work closely with the company’s business development teams and therapeutic area leaders to help shape investment strategies that fuel scientific discovery and advance clinical development.

Guild Executive Director Gerard Benedet said, “This acquisition is about reinvesting in our members and offering existing customers and clients even greater benefits. MBA aligns perfectly with our mission to support community pharmacies with innovative, cost-saving, and value-enhancing services.”

Head of Corporate Affairs Luke Cornish said, "Health literacy and trust are fundamentally interconnected. When patients understand their health information and feel respected by healthcare providers, they’re more likely to engage with the healthcare system."

The Australian caompany has announced compelling new preclinical data demonstrating the potential of its broad-spectrum antiviral Galidesivir to combat two of the world’s most lethal viral threats, Marburg and Ebola.

According to the Australian Dementia Network, therapies like KISUNLA represent a turning point in dementia care, and the registry’s role is critical in ensuring clinicians can translate innovation into best practice.